AN
ANIX.US Anixa Biosciences Inc
- Market cap
- USD 91.1M
- P/E
- -
- P/B
- 6.44x
- ROE
- -71.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jul 2026.
Is ANIX.US undervalued?
Graham numberThe Graham number of Anixa Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anixa Biosciences Inc fundamental analysis
No fundamental analysis for Anixa Biosciences Inc yet.
Anixa Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a …
Full company profileAnixa Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Anixa Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 300K | 363K | 1.11M | 250K | 0.00 | 512K | 2.47B | 210K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 82.6K | 258K | 18.8K | 83.8K | -90.2K | 127K | 2.47B | 49.0K | -37.0K | -36.0K | - |
| Operating Income | -4.51M | -6.08M | -13.7M | -11.9M | -9.98M | -13.1M | -13.9M | -11.0M | -13.8M | -11.7M | -10.8M |
| EBITDA | -4.14M | -4.14M | -13.9M | -11.0M | -10.0M | -13.1M | -13.7M | -9.88M | -12.7M | -11.0M | -10.5M |
| Net Income | -5.02M | -5.01M | -14.0M | -11.6M | -10.1M | -12.9M | -13.6M | -9.81M | -12.6M | -10.9M | -10.3M |
| EPS | -0.57 | -0.41 | -0.79 | -0.59 | -0.46 | -0.45 | -0.45 | -0.32 | -0.39 | -0.34 | -0.30 |
| Balance Sheet | |||||||||||
| Total Assets | 5.63M | 8.81M | 6.45M | 6.29M | 9.45M | 36.3M | 30.4M | 25.5M | 21.6M | 16.1M | 15.1M |
| Total Liabilities | 4.64M | 889K | 1.27M | 1.48M | 1.19M | 1.49M | 2.21M | 2.15M | 2.70M | 2.13M | 1.87M |
| Shareholders' Equity | 987K | 7.92M | 5.43M | 5.24M | 8.76M | 35.4M | 29.0M | 24.3M | 20.0M | 15.2M | 14.5M |
| Cash & Short-term Investments | 3.24M | 6.84M | 5.06M | 5.84M | 9.06M | 35.7M | 29.7M | 23.8M | 19.9M | 15.2M | 13.9M |
| Total Debt | 4.17M | - | - | - | 55.2K | 259K | 221K | 175K | 232K | 204K | 174K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.38M | -3.80M | -4.27M | -4.74M | -6.18M | -4.94M | -6.49M | -6.21M | -7.34M | -7.17M | -8.16M |
| Capital Expenditure | 147K | 30.2K | 38.4K | 175K | 15.8K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -3.53M | -3.83M | -4.31M | -4.92M | -6.19M | -4.94M | -6.49M | -6.21M | -7.34M | -7.17M | -8.16M |
| Ratios | |||||||||||
| ROE | -508.0% | -63.2% | -257.5% | -222.5% | -115.7% | -36.5% | -46.8% | -40.3% | -62.8% | -72.1% | -71.2% |
| ROA | -89.1% | -56.8% | -217.0% | -185.1% | -107.2% | -35.7% | -44.7% | -38.4% | -58.1% | -68.0% | -68.3% |
| Net Profit Margin | -1,672.1% | -1,381.8% | -1,258.1% | -4,658.8% | - | -2,528.6% | -0.6% | -4,671.9% | - | - | - |
| Debt to Equity | 4.22x | - | - | - | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Anixa Biosciences Inc dividends
Anixa Biosciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:25 on Jun 26, 2015.
Who owns Anixa Biosciences Inc
- Insiders 5.68%
- Institutions 14.63%
- Public & others 79.69%
- Shares outstanding 34.8M
- Free float 32.8M
Top funds holding ANIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 937K | 2.70% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 162K | 0.47% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 97.6K | 0.28% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 52.7K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 46.6K | 0.13% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 21.1K | 0.06% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 18.0K | 0.05% | 0.00% | Sep 2026 |
| Schwab Total Stock Market Index | 12.8K | 0.04% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 10.7K | 0.03% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 7.21K | 0.02% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 6.55K | 0.02% | -72.83% | Aug 2026 |
Top institutions holding ANIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 1.33M | 3.83% | +1.13% | Jun 2026 |
| UBS Group AG | 585K | 1.68% | +6.13% | Jun 2026 |
| Laird Norton Tyee Trust Co | 579K | 1.66% | +2.19% | Jun 2026 |
| Davidson D A & Co | 539K | 1.55% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 359K | 1.03% | -1.52% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 328K | 0.94% | +89.59% | Jun 2026 |
| BlackRock Inc | 200K | 0.57% | +17.43% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 192K | 0.55% | +0.67% | Jun 2026 |
| State Street Corp | 159K | 0.46% | 0.00% | Jun 2026 |
| GSA Capital Partners LLP | 117K | 0.34% | +18.84% | Jun 2026 |
| LPL Financial Corp | 112K | 0.32% | +37.74% | Jun 2026 |
| Northern Trust Corp | 69.2K | 0.20% | +3.61% | Jun 2026 |
| Renaissance Technologies Corp | 59.4K | 0.17% | -2.94% | Jun 2026 |
| CoreCap Advisors, LLC | 52.0K | 0.15% | 0.00% | Jun 2026 |
| Bank of New York Mellon Corp | 47.4K | 0.14% | 0.00% | Jun 2026 |
| Westside Investment Management, Inc. | 43.0K | 0.12% | -8.51% | Jun 2026 |
| HighTower Advisors, LLC | 41.2K | 0.12% | -0.96% | Jun 2026 |
| Kestra Advisory Services, LLC | 38.0K | 0.11% | -25.49% | Jun 2026 |
| CI Private Wealth LLC | 37.4K | 0.11% | +87.00% | Jun 2026 |
| Gemmer Asset Management LLC | 35.0K | 0.10% | 0.00% | Jun 2026 |
Anixa Biosciences Inc company profile
- Company name
- Anixa Biosciences Inc
- Ticker
- ANIX.US
- Exchange
- USA Stocks
- Listed since
- Jan 1, 1987
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- October
- Address
- 3150 Almaden Expressway, San Jose, CA, United States, 95118
- Phone
- 408 708 9808
- Website
- anixa.com
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Anixa Biosciences Inc management
3- Dr. Amit Kumar Ph.D.CEO, Chairman & Co-Chair of CBAB · born 1964
- Mr. Michael J. Catelani CPA, MBAPresident, COO, CFO & Corporate Secretary · born 1967
- Dr. Pamela D. Garzone Ph.D.Chief Development Officer & Chair Breast Cancer Clinical Advisory Board · born 1955